Novartis announces Lancet publication of pioneering study in migraine prevention showing efficacy of Aimovig where other treatments have failed
- The LIBERTY trial is the first study of a CGRP-targeted therapy in a patient population where multiple preventive treatments had previously failed
- Patients treated with Aimovig, reported significant reductions in monthly migraine days and a substantially improved ability to take part in daily activities vs placebo
- Tolerability and safety profile of Aimovig was similar to placebo, in line with data seen across the clinical trial program of over 3,000 patients?
- Aimovig is the first and only FDA and EMA approved CGRP-targeted therapy specifically designed for migraine prevention
- The primary endpoint showed that more than twice as many patients on Aimovig had their migraine days cut by 50% or more (30% vs.14%; odds ratio 2.7, p=0.002)
- Almost three times as many patients on Aimovig had their migraine days cut by 75% or more (12% vs. 4%; odds ratio 3.2, p=0.025, secondary endpoint)
- 6% of patients on Aimovig were completely migraine free (migraine days cut by 100%) vs no patients (0%) on placebo (secondary endpoint)
- Patients on Aimovig experienced a substantial reduction in monthly migraine days (MMD) (1.8 vs 0.2 fewer MMD, p=0.004, secondary endpoint)
- Those in the Aimovig arm reported significant reductions in the number of days per month using acute migraine-specific medication (1.3 reduction vs 0.5 day increase; p<0.001, secondary endpoint)
- Overall, the tolerability and safety profiles for Aimovig were similar to placebo, in keeping with findings throughout the drug's clinical trial program of over 3,000 patients